泽布替尼、奥妥珠单抗和维奈克拉联合方案以微小残留病驱动停药治疗初治慢性淋巴细胞白血病或小淋巴细胞淋巴瘤:多中心、单臂、2期试验
这项多中心单臂2期试验评估BOVen方案(泽布替尼+奥妥珠单抗+维奈克拉)治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤,以微小残留病(MRD)驱动停药。39例患者入组,中位随访25.8个月后,33/37例(89%,95%CI 75-97)在外周血和骨髓均达到不可检测MRD,中位治疗仅10个周期。方案耐受良好,支持进一步评估该方案及早期MRD反应指导疗程。
要点
- BOVen方案治疗初治CLL/SLL,33/37例(89%)达到外周血和骨髓不可检测MRD。
- 中位治疗10个周期即达到预设MRD停药标准,中位随访25.8个月。
- 最常见不良事件为血小板减少(59%)、疲乏(54%)、中性粒细胞减少(51%)和瘀斑(51%)。
核心结论
- BOVen方案耐受良好并达到主要终点,33/37例(89%)初治CLL/SLL患者在外周血和骨髓达到不可检测MRD,中位治疗仅10个月,归因于MRD驱动停药设计。
- 数据支持进一步评估BOVen方案治疗CLL/SLL并以早期MRD反应动力学指导疗程。
研究设计与样本
- 多中心、研究者发起的单臂2期试验,在美国两个学术医疗中心开展。
- 主要队列入组需治疗的初治CLL/SLL患者,年龄≥18岁,ECOG体能状态≤2分。
- BOVen方案按28天周期给药:泽布替尼160 mg口服每日两次自第1周期第1天开始;奥妥珠单抗1000 mg静脉给药于第1周期第1、8、15天及第2-8周期第1天(若绝对淋巴细胞计数>25000 cells/μL或淋巴结>5 cm,第1天分为100 mg和第2天900 mg);维奈克拉自第3周期第1天开始 ramp up 至400 mg每日。
- 达到预设外周血和骨髓不可检测MRD标准后,于8-24周期后停药。
- 主要终点为按方案评估的外周血和骨髓均达到不可检测MRD(流式细胞术 cutoff <10⁻⁴)的患者比例。
主要发现
- 28/39例(72%)为IGHV未突变,5/39例(13%)有17p缺失或TP53突变。
- 中位随访25.8个月(IQR 24.0-27.3)后,33/37例(89%,95%CI 75-97)在外周血和骨髓均达到不可检测MRD,满足预设停药标准,中位治疗10个周期(IQR 8-12)。
- 停药后中位监测15.8个月(IQR 13.0-18.6),31/33例(94%)维持不可检测MRD。
- 最常见不良事件:血小板减少23/39例(59%)、疲乏21/39例(54%)、中性粒细胞减少20/39例(51%)、瘀斑20/39例(51%);意向治疗人群中≥3级最常见为中性粒细胞减少7/39例(18%)。
- 1例死亡:第1周期第1天因肺栓塞启动静脉肝素后发生颅内出血。
关键数值与推荐
- 不可检测MRD标准:流式细胞术 cutoff <10⁻⁴(每10000个白细胞中少于1个CLL细胞)。
- 主要终点:外周血和骨髓均达到不可检测MRD的患者比例。
- 预设停药标准:达到不可检测MRD标准后于8-24周期后停药。
临床怎么用
- 作者认为数据支持进一步评估BOVen方案治疗CLL/SLL,并以早期MRD反应动力学指导疗程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable minimal residual disease (MRD), and we explored MRD as a biomarker for directing treatment duration. METHODS: This multicenter, investigator-initiated, single-arm, phase 2 trial took place at two two academic medical centres in the USA. Patients were eligible for the primary cohort if they had treatment-naive chronic lymphocytic leukaemia or small lymphocytic lymphoma, required therapy, and were at least 18 years of age with an Eastern Cooperative Oncology Group performance status up to 2. BOVen was administered in 28 day cycles (oral zanubrutinib at 160 mg twice per day starting in cycle 1 on day 1; intravenous obinutuzumab at 1000 mg on day 1 [split over day 1 with 100 mg and day 2 with 900 mg for an absolute lymphocyte count >25 000 cells per μL or lymph nodes >5 cm in diameter], day 8, and day 15 of cycle 1, and day 1 of cycles 2-8; and oral venetoclax ramp up to 400 mg per day starting in cycle 3 on day 1) and discontinued after 8-24 cycles when prespecified undetectable MRD criteria were met in the peripheral blood and bone marrow. The primary endpoint was the proportion of patients that reached undetectable MRD in both the peripheral blood and bone marrow (flow cytometry cutoff less than one chronic lymphocytic leukaemia cell per 10 000 leukocytes [<10-4]) assessed per protocol. This trial is registered at clinicaltrials.gov (NCT03824483). The primary cohort is closed to recruitment, and recruitment continues in the TP53-mutated mantle cell lymphoma cohort. FINDINGS: Between March 14, 2019, and Oct 10, 2019, 47 patients were screened for eligibility, and 39 patients were enrolled and treated. Median age was 62 years (IQR 52-70) with 30 (77%) of 39 male participants and nine (23%) of 39 female participants. 28 (72%) of 39 patients had unmutated immunoglobulin heavy-chain variable-region and five (13%) of 39 had 17p deletion or TP53 mutation. After a median follow-up of 25·8 months (IQR 24·0-27·3), 33 (89%) of 37 patients (95% CI 75-97) had undetectable MRD in both blood and bone marrow, meeting the prespecified undetectable MRD criteria to stop therapy after a median of ten cycles (IQR 8-12), which includes two cycles of zanubrutinib and obinutuzumab before starting venetoclax. After median surveillance after treatment of 15·8 months (IQR 13·0-18·6), 31 (94%) of 33 patients had undetectable MRD. The most common adverse events were thrombocytopenia (23 [59%] of 39), fatigue (21 [54%]), neutropenia (20 [51%]), and bruising (20 [51%]), and the most common adverse event at grade 3 or worse was neutropenia (seven [18%]) in the intention-to-treat population. One death occurred in a patient with intracranial haemorrhage on day 1 of cycle 1 after initiating intravenous heparin for pulmonary emboli. INTERPRETATION: BOVen was well tolerated and met its primary endpoint, with 33 (89%) of 37 previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma reaching undetectable MRD in both peripheral blood and bone marrow despite a median treatment duration of only 10 months, owing to our undetectable MRD-driven treatment discontinuation design. These data support further evaluation of the BOVen regimen in chronic lymphocytic leukaemia and small lymphocytic lymphoma with treatment duration guided by early MRD response kinetics. FUNDING: Beigene, Genentech (Roche), Grais-Cutler Fund, Lymphoma Research Fund, Lymphoma Research Foundation, American Cancer Society, Farmer Family Foundation, and the National Instititutes of Health and National Cancer Institute.
引用
- Soumerai JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021. PMID: 34826411. doi:10.1016/S2352-3026(21)00307-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。